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Summary
To facilitate the evaluation of ATM heterozygotes for
susceptibility to other diseases, such as breast cancer, we
have attempted to define the most common mutations
and their frequencies in ataxia-telangiectasia (A-T) ho-
mozygotes from 10 ethnic populations. Both genomic
mutations and their effects on cDNAwere characterized.
Protein-truncation testing of the entire ATM cDNA de-
tected 92 (66%) truncating mutations in 140 mutant
alleles screened. The haplotyping of patients with iden-
tical mutations indicates that almost all of these repre-
sent common ancestry and that very few spontaneously
recurring ATM mutations exist. Assays requiring min-
imal amounts of genomic DNA were designed to allow
rapid screening for common ethnic mutations. These
rapid assays detected mutations in 76% of Costa Rican
patients (3), 50% of Norwegian patients (1), 25% of
Polish patients (4), and 14% of Italian patients (1), as
well as in patients of Amish/Mennonite and Irish English
backgrounds. Additional mutations were observed in
Japanese, Utah Mormon, and African American pa-
tients. These assays should facilitate screening for A-T
heterozygotes in the populations studied.
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Introduction
Ataxia-telangiectasia (A-T) is an autosomal recessive dis-
order with a frequency of 1/40,000–1/100,000 (Swift et
al. 1986). The disorder is characterized by progressive
cerebellar ataxia, oculocutaneous telangiectasia, cellular
and humoral immune deficiency, chromosomal instabil-
ity, sensitivity to ionizing radiation, and increased inci-
dence of cancer (Boder and Sedgwick 1958; Sedgwick
and Boder 1991; Gatti 1997). Heterozygotes are also at
an increased risk of developing cancer, especially breast
cancer (Swift et al. 1987, 1991; Pippard et al. 1988;
Borresen et al. 1990; Easton 1994; Athma et al. 1996)
and possibly T cell leukemia (Vorechovsky et al. 1997);
however, they are otherwise asymptomatic. The gene
responsible for the disease, ATM, was localized to chro-
mosome 11q22-23 (Gatti et al. 1988; Lange et al. 1995)
and was subsequently isolated by positional cloning
(Savitsky et al. 1995a).
There is great interest in screening cancer-risk popu-
lations for mutations in the ATM gene (Vorechovsky et
al. 1996a, 1997; FitzGerald et al. 1997). However, with
141 mutations already described in A-T homozygotes
(Savitsky et al. 1995a; Baumer et al. 1996; Byrd et al.
1996; Gilad et al. 1996a, 1996b; Lakin et al. 1996;
McConville et al. 1996; Telatar et al. 1996; Vorechovsky
et al. 1996b; Wright et al. 1996; Watters et al. 1997),
and with another 100 either still unpublished or de-
scribed herein, the spectrum of mutations that is emerg-
ing creates significant technical problems for population
screening. The ATM gene is large, containing 66 small
exons encoding a 13-kb transcript. Most mutations are
unique, and they are distributed uniformly along the
length of the gene, with no obvious “hot spots.” Ap-
proximately 70% of published mutations would trun-
cate the ATM protein and should be detectable by pro-
tein-truncation testing (PTT).
In this report, we demonstrate that (1) PTT detected
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Table 1
Primers Used in PTT Analysis and Rapid Detection of Ethnic
Mutations
PTT Fragment or Exon
Nucleotide Sequencea
(5′–3′)
PTT fragment (nucleotide
position):
Region e (76–1392):
Forward (T7)-GAAGTTGAGAAATTTAAGC
Reverse AATGCAACTTCCGTAAGGC
Region f (1048–2817):
Forward (T7)-GCAGATATCTGT
Reverse GTAGGTTCTAGCGTGCTAGA
Region g (2437–4092):
Forward (T7)-AATGACATTGCAGATATTT
Reverse TCAGTGCTCTGACTGGCACT
Region a (4048–5435):
Forward (T7)-ACGTTACATGAGCCAG
Reverse TCCAAATGTCATGATTTTCAC
Region b (5282–6529):
Forward (T7)-CTGGCCTATCTACAGC
Reverse CAACCTGCTAAGTGTGGGAT
Region c (6322–7856):
Forward (T7)-CAGTGGGACCATTGC
Reverse TTCTGACCATCTGAGGTCTCC
Region d (7651–9172):
Forward (T7)-GATCACCCCATCACA
Reverse TCACACCCAAGCTTTCCATC
Exon:
12:
Forward GCTTACTTGGAGCCATAATTC
Reverse TGAAGGTCTGCAGGCTGAC
24:
Forward TGGGAAAAGACTTTCCTGTAAA
Reverse CTATTGATTGACTCTGCAGCC
41:
Forward CTCTATGCAGAAATCTATGCAG
Reverse ATACCCTTATTGAGACAATGCC
42:
Forward GTATATGTATTCAGGAGCTTC
Reverse ATGGCATCTGTACAGTGTCT
43:
Forward CAGAACTGTATTTCAGAATCAT
Reverse ACATAACTCCTTCATAAACAGA
50:
Forward AGTTGGGTACAGTCATGGTA
Reverse GAAAAGATGAAGCATATTCATG
52:
Forward ATTAAGTGGAGAACCACATGATA
Reverse ATGCCATTGACTTCAGAAAC
53:
Forward TTACTTGCTTAGATGTGAGA
Reverse ATATGTTGGAATCTTCATTCCG
54:
Forward AAGCAAAATGAAAAATATGG
Reverse AAGTGTGATGGGGGTGA
a “(T7)” indicates the sequence GGATCCTAATACGAC-
TCACTATAGGAACAGACCACCATG.
66% (92/140) of mutant alleles, (2) almost all recurring
mutations share haplotypes and represent “founder ef-
fects,” and (3) it is possible to approach carrier testing
by first identifying the most common mutations in se-
lected ethnic populations and then developing rapid as-
says that use small amounts of genomic DNA and less
costly methods. We have detected many relatively com-
mon founder-effect mutations in Norwegian, Costa Ri-
can, Polish, Italian, and Amish/Mennonite populations,
and we have analyzed other, less common mutations in
patients of Irish, English, Japanese, Utah Mormon, and
African American backgrounds. The rapid assays de-
scribed herein should facilitate heterozygote screening in
these populations.
Subjects and Methods
Subjects
We initially used PTT to analyze cDNAs from 70 un-
related patients with various ethnic backgrounds. We
later used rapid assays, based on the PTT results, to
detect specific mutations in DNAs from 8 Norwegian
families, 27 Costa Rican patients (previously described
by Uhrhammer et al. [1995]), 22 Polish patients, 28
Italian patients, and several Amish/Mennonite families,
as well as in DNAs from 40 normal individuals (CEPH
parents; northern European backgrounds [Dausset et al.
1990]).
Primers
The ATM cDNA sequence was divided into seven
overlapping fragments (e, f, g, a, b, c, and d), and each
fragment was subjected to PTT. Primers used for the PTT
analysis of the entire ATM cDNA are shown in table 1.
Primers used in rapid assays, also shown in table 1, were
designed on the basis of sequences reported by Savitsky
et al. (1995a; 1995b), Rasio et al. (1995), and personal
communications from M. Platzer and A. Rosenthal (ac-
cession number U82828; Platzer et al. 1997). Primers
for exons 42, 43, and 50 were designed by A. Tolun and
S. Onengut.
Haplotype Analyses
Panels of 6–15 genetic markers located across the
ATM gene region were used to create haplotypes (Gatti
et al. 1994; Vanagaite et al. 1995; Uhrhammer et al.
1995).
Heteroduplex Analysis
Heteroduplexes were formed by mixing the PCR
products of an A-T patient with PCR product of a nor-
mal individual. The DNA mixture was then denatured
at 95C for 5 min and was allowed to reanneal at 55C
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Figure 1 Spectrum of ATM mutations, based on 205 mutations. Boxes represent founder-effect mutations, identified by shared haplotypes.
for 45 min. Samples were run on a 12% polyacrylamide
gel, under nondenaturing conditions, for 1.5 h at 120
V. Bands were visualized by staining the gel with ethi-
dium bromide.
RNA Isolation, cDNA Synthesis, and PTT
These methods have been described elsewhere (Telatar
et al. 1996); primers for the seven PTT-screening seg-
ments are described in table 1. Protein products of the
coupled PTT reaction were run on 10%–20% gradient
SDS-PAGE gels for 5 h at 250 V.
Nomenclature
ATM mutations were initially detected in cDNAs de-
rived from lymphoblastoid cell lines of A-T patients. The
underlying genomic mutation sites often differed from
the cDNA sequence locations when splice sites were in-
volved. Because the official nomenclature report states
that the recommendations for describing splicing mu-
tations “will provide a unique identifier but will not call
attention to the effect on splicing” (Ad Hoc Committee
on Mutation Nomenclature 1996, p. 201), in this report
we describe all mutations first by the official nomencla-
ture of nucleotide position (e.g., 6095GrA); second, by
the first affected codon (e.g., codon 2003); and, last, by
the effect of the mutation on the cDNA (e.g., del89nt):
6095GrA (codon 2003del89nt). We have included the
first affected codon for most mutations because prior
publications have used a variety of numbering systems
for both nucleotides and exons, whereas codon num-
bering has remained unchanged. A website for ATM
mutations (http://www.vmmc.org/vmrc/atm.htm) gives
both further details on the nomenclature and updates
on mutations reported previously.
Results
By using the PTT to screen cDNA, we detected 92
(66%) truncating mutations in 140 mutant chromo-
somes. This figure approximated the predicted number
of truncating mutations (i.e., 70%) (Telatar et al. 1996).
Figure 1 depicts the spectrum of all published ATM
mutations (Savitsky et al. 1995a, 1995b; Baumer et al.
1996; Byrd et al. 1996; Gilad et al. 1996a, 1996b; Lakin
et al. 1996; McConville et al. 1996; Telatar et al. 1996;
Vorechovsky et al. 1996b; Wright et al. 1996), including
those reported herein, as well as ∼50 unpublished mu-
tations identified in our laboratories. Although the spec-
trum observed is generally diverse, we have noted several
positions at which the same mutation has been described
in multiple patients. So as not to bias the emerging spec-
trum of ATM mutations, those associated with shared
haplotypes are represented only once, and a box has
been placed above those locations in figure 1. These are
considered founder-effect mutations and are summarized
in table 2. We designed rapid assays for some of the
more common mutations, using genomic DNA as the
template for PCR amplification. These assays were also
used to screen normal populations, to determine whether
some mutations might in fact be common polymor-
phisms; none of these mutations were observed in 40
persons of northern European background.
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Table 2
ATM Mutations in Ethnic Populations
Codon Number cDNA Mutation Genomic Mutation Ethnic Origin
144 insA 432insA Polish
522a delAG 1563delAG Amish
536 ins764nt IVS121GrT Italian
750 ins9nt IVS1610TrG African American
834 insA 2502insA Italian
937 insCTAG 2810insCTAG African American
1026 del207nt 3214GrT Polish
1029 insA 3084insA Polish
1081 ATCrTGAT 3245ATCrTGAT Norwegian
1135 del174nt 3576GrA Italian
1537 ins11 IVS3212ArG Utah Mormon
1921a ins137nt IVS401126ArG English Midland
1970 CrT 5908CrT Costa Rican
1973 del88nt 5932GrT Polish Mennonite
2003a del89nt 6095GrA Polish
2271a delC 6810delC Italian
2337a delGT 7010delGT Polish
2443a CrT 7327CrT African American
2481 del70nt 7449GrA Costa Rican
2506a del4nt 7517del4nt Italian, French
2544a del298nt 7926ArC African American
2544a del159nt IVS532ArC Polish
2546a del9nt 7636del9nt Irish English
2628a del5nt 7883del5nt Japanese
2832 CrT 8494CrT Utah Mormon
2891a del115nt IVS621GrA Utah Mormon
2922 insT 8766insT Polish
2941a ins4nt 8822ins4nt Italian
2945a delCT 8833delCT Italian
2951 del17kb IVS63del17kb Costa Rican
a Published previously; see Results.
Norwegian Mutation: 3245ATCrTGAT (codon 1081)
Two Norwegian patients showed protein truncation
in PTT-screening region g; one was homozygous for the
same truncated band, and the other was heterozygous
(fig. 2a). Sequence analysis revealed a complex frame-
shift mutation, 3245ATCrTGAT (codon 1081), in exon
24. Primers flanking the mutation were designed from
genomic DNA sequence. Genomic DNA from eight un-
related Norwegian A-T patients (including the two pa-
tients mentioned above) and their siblings was amplified
for this region, and the PCR products were subjected to
heteroduplex analysis (fig. 3). Three patients were found
to be homozygous, and two were found to be hetero-
zygous, for this mutation. Haplotype analysis with seven
markers demonstrated that all five patients who had the
mutation shared the same haplotype. Thus, among Nor-
wegian A-T patients, one mutation accounted for half
(8 of 16) of the mutant alleles. An American patient of
Norwegian ancestry was also found to have this
mutation.
Costa Rican Mutations
In a previous study, 10 distinct haplotypes were ob-
served in 27 Costa Rican A-T patients (Uhrhammer et
al. 1995). Further testing with two newer markers
(D11S1778 and D11S2179) has refined our ability to
distinguish haplotypes A, A′, and B from one another.
Other than this, the original haplotype assignments of
A–J have been retained. The haplotypes A, B, C, and D
account for, respectively, 56%, 7%, 13%, and 9% of
the 27 Costa Rican patients studied. We have identified
the mutations of haplotypes A, B, and C.
Haplotype A (5908CrT [codon 1970]).—PTT of a
haplotype A patient demonstrated protein truncation in
region b (fig. 2b). Sequence analysis identified the mu-
tation as a CrT transition in exon 41, at position 5908
(codon 1970). The mutation abolishes a Sau3AI diges-
tion site. Primers flanking the mutation were designed
from genomic DNA sequence. When digested with
Sau3AI, the PCR product (116 bp) of a normal individ-
ual produced two bands, of sizes 77 bp and 39 bp. The
5908CrT mutation abolishes the Sau3AI site, and only
one band, of size 116 bp, was observed in patients who
were homozygous for haplotype A. Genomic DNA from
all Costa Rican patients was PCR amplified across this
region and was digested with Sau3AI, and the products
were electrophoresed on a 3:1 NuSieve agarose gel (fig.
4). Eleven patients were found to be homozygous, and
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Figure 2 Protein truncation test results. a, Norwegian patients:
PTT-screening region g. Lane 1 shows results for a normal control,
and lanes 2 and 3 show results for patients with truncated protein of
33 kD (one homozygous, the other heterozygous). b, Costa Rican
patients: PTT-screening region b. Lane 1 shows results for a normal
control, and lanes 2 and 3 show results for homozygous patients with
truncated protein of 25 kD.
Figure 3 Heteroduplex and haplotype analysis of a Norwegian
family. Lane 1 is a heteroduplex mixture of DNA from an affected
child and a normal child, lane 2 is the affected child alone, and lanes
3–5 are heterozygotes. Bracketed letters indicate corresponding hap-
lotypes. Parents (lanes 4 and 5) carry the same mutation; consanguinity
was denied.8 patients were found to be heterozygous, for the
5908CrT mutation. This result was in complete agree-
ment with prior haplotyping data (Uhrhammer et al.
1995). Patients with the A′ haplotype had the same mu-
tation as was seen in those with haplotype A. The fre-
quency of the 5908CrT mutation in 27 Costa Rican
patients was 56%.
Haplotype B (IVS63del17kb).—The haplotype B mu-
tation (IVS63del16kb) is a 17-kb deletion that begins in
intron 63 and ends beyond the 3′ UTR. Southern blot
analysis with BglII digestion showed that DNA from a
homozygous haplotype B patient fails to hybridize with
probes for exon 64 or exon 65. The deletion begins and
ends in two LINES repeats. Three Costa Rican patients
(7.4%) shared the B haplotype. This is only the second
“large” deletion described to date (Savitsky et al. 1995a)
in the ATM gene.
Haplotype C (7449GrA [codon 2481del70nt]).—A
haplotype C patient showed truncation in PTT-screening
region c. Sequencing of genomic DNA identified the mu-
tation (7449GrA [codon 2481del70nt]) as a homozy-
gous GrA transition at position 7449. Because the mu-
tation does not create or abolish any known restriction
sites, we designed a forward primer that contains CC
instead of GA, as indicated by underlines in table 1 (exon
52). PCR amplification with this primer introduces an
XcmI site (CCANNNNNNNNNTGG) in normal DNA,
so that an 86-bp PCR product becomes two bands, 66
bp and 20 bp, in normal individuals; DNA from patients
with the 7449GrA mutation remained undigested (data
not shown). The location of the mutation is underlined
in the XcmI site above. Haplotype C was observed in 7
(13%) of 54 chromosomes. This result confirmed the
original haplotyping by Uhrhammer et al. (1995).
Polish Mutations
We analyzed haplotypes of 22 Polish A-T patients for
linkage disequilibrium (data not shown). Ten patients
with representative haplotypes were screened by use of
PTT. We identified eight distinct mutations. Rapid assays
were designed for five of these, comprising 27% of the
mutant alleles, and were used to screen all 22 Polish
patients, several American patients of Polish ancestry,
and 80 normal chromosomes of non-Polish origin
(CEPH families). None of these mutations were found
in normal individuals. Further testing for these muta-
tions in the Polish population is under way (by E.B.-
M.).
Haplotype A (IVS53-2ArC [codon 2544del-
159nt]).—This mutation results in a deletion of exon 54,
beginning at codon 2544. The genomic mutation alters
the invariant splice-acceptor site at 2 from exon 54
(Wright et al. 1996). The mutation abolishes an AluI
site. Primers flanking the mutation were designed from
genomic sequence. When normal DNA was digested
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Figure 4 Sau3AI digestion of 11 PCR products from Costa Rican
patients. Lanes 1 and 15 are undigested (U) samples, and lanes 2 and
14 are digested normals (N); lanes 3–10 are A-T patients who were
homozygous for haplotype A and are homozygous for the 5908CrT
mutation, as indicated by the undigested bands. Lanes 11–13 are com-
pound heterozygotes showing both digested and undigested bands.
with AluI, a 110-bp PCR product was divided into bands
of 70 bp and 40 bp; the 110-bp PCR product of alleles
with this mutation remained undigested (fig. 5a). Of
seven A-T patients with deletions of exon 54 that were
identified by use of reverse transcriptase–PCR based
tests, four patients with this mutation were identified by
use of genomic testing. All of these patients (W1, W15,
W23, and W24) were Polish and shared haplotype A
(fig. 5f). Among Polish A-T patients, this allele repre-
sented 9% of mutant alleles.
Haplotype B (6095GrA [codon 2003del89nt]).—This
mutation involves a GrA substitution of the last nucle-
otide of exon 43, and it results in the deletion of exon
43 from the cDNA. The mutation abolishes a BfaI site.
Primers flanking the mutation were designed from ge-
nomic sequence. After digestion with BfaI, a 301-bp
PCR product from normal individuals showed two
bands, 239 bp and 62 bp, whereas patients with the
6095GrA mutation showed only the undigested 301-
bp product. Genomic DNA from 22 Polish A-T patients
was screened for this mutation; 3 (W8, W19, and W22)
were found to be heterozygous (fig. 5b). These three
patients (3 [6.8%] of 44) shared haplotype B (fig. 5f).
Haplotype C (7010delGT [codon 2337]).—Two of 22
patients were found to be heterozygous for the haplotype
C mutation. Deletion of GT at position 7010 in exon
50 creates a TfiI site. Genomic DNAs were amplified
with primers flanking exon 50, and the products were
digested with TfiI. A 231-bp PCR product remained un-
digested in normal individuals, whereas the two patients
(W1 and W9) with this mutation produced two bands,
141 bp and 88 bp (fig. 5c). These two patients (2 [4.5%]
of 44) shared haplotype C (fig. 5f).
Haplotype D (5932GrT [codon 1973del88nt]).—This
mutation creates a stop codon (GAA[Glu]rTAA
[stop]). In cDNA, exon 42—where this mutation oc-
curs—is frequently deleted. The GrT transversion cre-
ates an MseI site. Primers flanking the mutation were
designed from genomic DNA sequence. When the nor-
mal 232-bp PCR product was digested with MseI, two
bands, 33 bp and 199 bp, were observed, whereas pa-
tients with the 5932GrT mutation produced three
bands, of 33 bp, 40 bp, and 159 bp (fig. 5d). Genomic
DNAs of 22 Polish A-T patients were screened, and 2
(W3 and W10) were found to be heterozygous for this
mutation. These 2 patients (2 [4.5%] of 44) shared hap-
lotype D (fig. 5f).
Mutation 3214GrT (codon 1026del207nt).—This
mutation in exon 24 also results in the creation of a stop
codon (GAA[Glu]rTAA[stop]). In cDNA, a variant
form of mRNA was observed in which exons 23 and
24 were deleted, thereby splicing over this mutation and
maintaining the correct reading frame. The mutation
creates an MseI site. PCR primers flanking the mutation
were designed from genomic DNA sequences. After di-
gestion with MseI, a 94-bp PCR product remained un-
digested in normal individuals, whereas patients with
this mutation produced two bands, 71 bp and 23 bp
(fig. 5e). Genomic DNA of 22 Polish A-T patients was
amplified for exon 24 (with the same primers used for
detecting the 3245ATCrTGAT Norwegian mutation)
and was digested with MseI; only 1 Polish patient (W6)
was found to be heterozygous for this mutation.
Thus, the Polish population appears to contain at least
four founder-effect mutations, comprising 25% of the
patients studied. Rapid assays were designed and tested
for all four. We identified three additional mutations in
Polish patients, for which rapid assays were not de-
signed: 432insA (codon 144), 3084insA (codon 1029),
and 8766insT (codon 2922); all were compound
heterozygotes.
Italian Mutations
Gilad et al. (1996a, 1996b) reported a founder-effect
deletion of 4 nt at position 7517 in exon 53 (7517del4nt
[codon 2506]), found in six patients from central-south-
ern Italy (fig. 1, box over exon 53). This mutation has
also been reported in a French patient (Vorechovsky et
al. 1996b). To determine the frequency of this mutation
among other A-T patients of Italian ancestry, we de-
signed, from genomic sequence, primers flanking the mu-
tation, and we tested the PCR products by heteroduplex
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Figure 5 Comparison of Polish mutations and haplotypes. U  undigested DNA, and N  normal control. a, Haplotype A mutation,
IVS53-2ArC. Lanes 3–5 are heterozygous patient samples, and lane 6 is a patient with a cDNA deletion of exon 54 who does not have the
IVS53-2ArC genomic mutation. Haplotype analysis shows that patients in lanes 3–5 share haplotype A (data shown in f), whereas the patient
in lane 6 does not share this haplotype (data not shown). b, Haplotype B mutation, 6095GrA(2003del89nt). Three heterozygous Polish patients
(lanes 3–5) have the 6095GrA(2003del89nt) mutation in exon 43. c, Haplotype C mutation, 7010delGT. Lanes 1 and 2 are patients who have
the 7010delGT mutation in exon 50. Lanes 3 and 4 are patients who do not have this mutation. d, Haplotype D mutation, 5932GrT. MseI
digestion assay was performed on samples from six Polish patients (lanes 3–8). Lanes 4 and 8 are patients with the 5932GrT mutation in
exon 42. e, 3214GrT mutation. Assay was performed on samples from three Polish patients (lanes 1–3). Lane 1 is a patient with the 3214GrT
mutation in exon 24. f, Haplotype analysis of the 10 Polish patients described above. Shaded areas represent four shared haplotypes (A–D).
analysis. Twenty-eight patients were screened. Two pa-
tients showed this mutation; both were homozygous (fig.
6) and shared the same two haplotypes at chromosome
11q23.1 (4 [7%] of 56 mutant alleles).
Screening by use of PTT identified five other mutations
in A-T patients of Italian ancestry. We previously had
reported three mutations, at 6810delC (codon 2271),
8822ins4nt (codon 2941), and 8833delCT (codon 2945)
(Telatar et al. 1996). Three new mutations were detected
by use of PTT screening: 3576GrA (codon
1135del174nt), IVS121GrT( codon 536ins764nt),
and 2502insA (codon 834). The 3576GrA (codon
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Figure 6 Heteroduplex and haplotype analysis of two homo-
zygous Italian patients showing the 7517del4 mutation (Savitsky et al.
1995a). Lanes 1a and 2a are the patient samples; lanes 1b and 2b are
the heteroduplex mixture of DNAs from normal individuals with those
of patients 1a and 2a, respectively; and lane 3 is a normal control.
Haplotype analysis has shown that both patients share both haplotypes
at chromosome 11q23.1.
Figure 7 Heteroduplex and haplotype analysis of a consan-
guineous Amish family showing the inheritance of the 1563delAG
mutation. Haplotype analysis has shown that the mutation is inherited
through haplotypes B and C (Lange et al. 1993). Heteroduplex analysis
confirms that any person in the family with either haplotype B or
haplotype C is a carrier for the mutation.
1135del174nt) mutation was observed in 4 (7%) of 56
mutant alleles. Rapid assays have not yet been designed
for any of these mutations.
Amish/Mennonite Mutations
The mutation in the original Amish family used to
localize the A-T gene (Gatti et al. 1988) was a deletion
of AG at position 1563 in exon 12 (codon 522) (Savitsky
et al. 1995a). PCR primers flanking the mutation were
designed from genomic DNA sequence. The remaining
71 members of the pedigree were screened for the mu-
tation by use of heteroduplex analysis (fig. 7). The three
affected individuals in the pedigree were found to be
homozygous for this mutation, as well as for all adjacent
markers, as expected. All expected heterozygotes (Gatti
et al. 1988; Lange et al. 1993) were confirmed by use
of the heteroduplex assay.
We also screened three patients, from two families of
Mennonite background, who were residents of British
Columbia (Pohl et al. 1992) and Belize. We did not ob-
serve the 1563delAG (codon 522) mutation or the ex-
pected Amish haplotype in these families. Lymphoblas-
toid cell lines from these patients were further tested for
radiosensitivity, and they showed the characteristic
decreased postradiation colony survival of A-T cells
(Huo et al. 1994) (data not shown). Subsequent PTT
screening identified a second mutation, 5932GrT (co-
don 1973del88nt), which was common to both families.
This mutation is described above in two Polish patients
who shared a common haplotype. We found the same
haplotype in the two Mennonite families of non-U.S.
origin. Both Mennonite families have northern European
surnames, and the data are compatible with the histor-
ical record of a Dutch-Polish Mennonite migration to
southern Russia and then to North America at the end
of the 18th century (Hostetler 1983, p. 17).
English Midlands Mutation: IVS401126ArG (codon
1921ins137nt)
This intriguing founder-effect mutation, affecting
∼15% of U.K. patients, was described by McConville
et al. (1996) in a group of 16 families (12 homozygotes,
6 compound heterozygotes) who shared a common
“418” haplotype (defined by alleles 4, 1, and 8, respec-
tively, of markers D11S1817, D11S1343, and
D11S1819), as well as intermediate radiosensitivity, a
milder phenotype, and lack of cancer susceptibility (Tay-
lor et al. 1994). Although five families were Scottish
(Taylor et al. 1994), all families traced their forebears
to the Midlands region of England. An ArG transition
within intron 40 creates a consensus splice-donor site
(gtaaagrgtaagg) that, when used, results in the insertion
of 137 nt into transcripts from this allele. However, de-
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tectable amounts of normal transcript are also produced
by this allele, with the potential to encode functional
ATM protein. It has been suggested that this normal
protein might be sufficient to moderate the phenotype
(McConville et al. 1996). Using PTT, we screened 70
purportedly unrelated patients of various ethnic back-
grounds, and we found two families with this mutation
(data not shown); both had English family names. In
one family, the onset of ataxia in two sibs occurred at
3 and 6 years of age; disease progress was slow. One
sibling lived to the age of 44 years. In the other family,
the age at onset of ataxia among the three affected sibs
was early or typical, occurring at 8 mo, 3.5 years, and
9 mo; despite this, disease progress has been slow. Can-
cer has not been observed in either family. Thus, this
fairly common English mutation may be associated with
a mild phenotype and a low frequency of cancer, and
this could distort the outcome of studies that screen can-
cer patients for this ATM mutation. Furthermore, special
primers nested within intron 40 must be included to
detect this mutation when one is screening genomic
DNA.
Irish English Mutation: 7636del9nt (codon 2546)
This mutation in exon 54 has been described in 16
A-T patients (Savitsky et al. 1995a; Gilad et al. 1996b;
McConville et al. 1996; Wright et al. 1996; present
study), most of whom either lived in the United Kingdom
or had Irish or English family names and lived in the
United States or Australia. The mutation has also been
observed in a Swedish breast cancer patient (Vorechov-
sky et al. 1996a). We have designed and tested a rapid
assay for its detection. The 9-nt deletion removes a BfaI
site; two bands (78 bp and 32 bp) were observed in
normal individuals, whereas patients with this mutation
showed only a single band (101 bp) (data not shown).
Using the same exon 54 primers used for detection of
the IVS53-2ArC mutation seen in Polish patients, we
observed this mutation in three additional A-T patients.
We determined the haplotypes for 6 of the 16 patients
with this mutation for whom DNA was available; 5
shared the same haplotype. Thus, our suggestion that
this is a frequent mutation among unrelated A-T patients
(Wright et al. 1996) now appears unlikely. More likely,
it is primarily a founder-effect mutation of Irish English
origin, comprising perhaps 10% of English patients. Us-
ing a similar rapid assay, Wright et al. (1996) failed to
observe the mutation in 1300 normal chromosomes.
Japanese Mutation
Gilad et al. (1996b) reported two ATM mutations in
Japanese patients. One of these mutations, 7883del5nt
(codon 2628), was homozygous in one patient and het-
erozygous in the second. We detected one copy of this
mutation in one additional patient of Japanese ancestry.
Thus, in a very limited survey, 7883del5nt accounts for
four of six mutant alleles described in the Japanese pop-
ulation. Haplotypes have not been compared for a foun-
der effect. This mutation is easily detected by use of
either SSCP or heteroduplex analysis.
Utah Mormon Mutations
We have identified three unique mutations in three
patients of Utah Mormon background. These patients
do not share haplotypes. One patient was homozygous
for IVS32-12ArG (codon 1537ins11nt); her mutation
resulted in the production of at least four transcripts, all
of which had an insertion of 11 nt in exon 33. In three
of the transcripts, we also observed exon skipping of
one or two exons (i.e., either exon 34 or exons 34 and
35). Two other patients were heterozygous for the fol-
lowing mutations: 8494CrT (codon 2832) and
IVS621GrA (codon 2891del115nt).
African American Mutations
Four mutations have been identified in two African
American patients. One patient was heterozygous for
mutations IVS16-10TrG (codon 750ins9nt) and
2810insCTAG (codon 937); the other patient, previously
described by Wright et al. (1996), was heterozygous for
mutations 7327CrT (codon 2443) and 7926ArC (co-
don 2544del298nt).
Discussion
Since 1200 ATM mutations in A-T patients have been
defined, we can now realistically assess the mutation-
detection methodology for this large gene. Virtually all
patients who are not of a consanguineous background
are compound heterozygotes. Few, if any, hot spots exist
in the gene. Most patients express transcripts for both
mutated alleles (Telatar et al. 1996). Approximately
70% of reported ATM mutations would result in a trun-
cated protein. However, it remains unclear whether mu-
tated ATM proteins, truncated or otherwise, are stable
in most A-T cells.
A wide array of mutation-detection techniques have
been tested. Since the gene is so large (∼150 kb), most
studies have used cDNA as the starting template. To
date, the single most effective method of screening cDNA
has been the PTT. We have detected 92 mutations in
140 chromosomes (66%). We have used conformation-
sensitive gel electrophoresis, as a complementary meth-
od, to screen 600–800-nt segments of ATM cDNA. This
has yielded ∼35 mutations/100 chromosomes screened,
including some that were identified by PTT as well
(Liang et al., unpublished data). Several laboratories
have used restriction-endonuclease fingerprinting to
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screen cDNA segments of 1,000–2,000 nt, with good
success (Liu and Sommer 1995; Savitsky et al. 1995a;
Byrd et al. 1996; Gilad et al. 1996b). However, because
all ATM exons are !372 nt (exon 12), none of these
methods are optimal or, in some cases, applicable to
screening genomic DNA. These assays also vary widely
in cost; PTT and SSCP cost ∼$100–$150/patient, as
compared to ∼$2,000–$4,000/patient for direct se-
quencing of the entire cDNA. Of course, these estimates
also depend on the stage of the analyses at which mu-
tations can be identified and at which testing can be
terminated. The rapid assays described herein can be
used to screen batches of 20–50 gDNAs, at a cost of
!$5 each (not including the costs of DNA isolation).
The current study reflects an alternative approach to
the technical challenges of population screening for A-
T carriers. To circumvent the problem of testing pro-
spectively for the many possible ATM mutations in car-
riers, we have sought to identify and to determine the
frequencies of mutations in ethnic populations where
founder effects or common mutations may be present.
With this information and with the rapid genomic
DNA–screening assays described in this report, we be-
lieve that carrier screening can be initiated in these lim-
ited populations.
On the basis of the mutations described above in A-
T patients of common ethnic backgrounds, we investi-
gated the spectrum of ATM mutations in 10 populations.
Common mutations were found in Norwegians, Costa
Ricans, Poles, Italians, and Japanese (on the basis of a
small sample of Japanese patients). Rapid genomic
screening assays were developed that detect 76% of mu-
tant ATM alleles in Costa Ricans, 50% in Norwegians,
27% in Poles, and 14% in Italians. The mutation de-
scribed most commonly in the literature, 7636del9,
probably constitutes a founder effect (see above). It can
be detected by either of two rapid assays (Wright et al.
1996; present study).
In the Amish population, our failure to find either the
common haplotype or the 1563delAG (codon 522) mu-
tation in Mennonite patients who were not members of
the immediate Pennsylvania/Ohio/Indiana extended
family was surprising. Of further interest, when all other
A-T patients were tested with the rapid gDNA assay for
this mutation, it was found in a non-Amish American
family and in a Turkish family. Byrd et al. (1996) have
also reported this mutation, in a family in the United
Kingdom. Thus, the 1563delAG (codon 522) mutation
accounts for 2% of the mutations described to date
worldwide; however, haplotypes of these patients have
not yet been compared to determine how many of them
share common ancestry. We also found a different mu-
tation, 5932GrT (codon 1973del88nt), in two non-U.S.
Mennonite families and in two Polish patients, with
shared haplotypes in all four families.
Each rapid assay allows large-scale screening of A-T
homozygotes with as yet unidentified mutations, and
these assays may be especially useful in analyzing pa-
tients of known ancestry. We have detected the Nor-
wegian and Italian mutations in some American families
of these ancestries, and this approach has allowed us to
rapidly determine the frequency of particular mutations
across a large sample of A-T homozygotes. Nonetheless,
we and others are still detecting primarily new muta-
tions, and we do not yet appear to be reaching a point
of saturation for new mutations.
Savitsky et al. (1995a) have provided strong evidence
against the existence of genetic heterogeneity. During the
positional cloning of the ATM gene, an international A-
T consortium genotyped 1200 families across 130 cM
at chromosome 11q22-23 (Lange et al. 1995). Approx-
imately 25 of those families were set apart for one reason
or another, usually because one member of the family
either had or lacked a clinical feature, calling the status
of the entire family into question. Such families had to
be prospectively excluded from linkage analyses. Seven
of the 176 families with firm diagnoses did not link to
11q23.1 (Gatti et al. 1994; Lange et al. 1995). One of
these seven, CRAT 10 (Uhrhammer et al. 1995), now
links, since a young child with two affected haplotypes
has subsequently developed ataxia. Of the other six, and
among many of the 25 “variant” families, at least one
ATM mutation has been identified in approximately
half. Several patients with ATFresno (Curry et al. 1989)
also harbor mutations in the ATM gene. Thus, it appears
unlikely that mutations in other genes will account for
more than a very small fraction of patients with the
characteristic A-T syndrome (Boder and Sedgwick 1958;
Boder 1985; Sedgwick and Boder 1991; Woods and Tay-
lor 1992; Lange et al. 1993; Bundey 1994; Gatti 1997).
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